BD Q2 fiscal 2023 revenue $4.82B, adjusted EPS $2.86; raises guidance

BECTON DICKINSON & CO

2023-Q2 EPS reported $3.24 revenue$9,407,000,000

Revenue $4.821B, up 1.5% reported (+4.1% currency-neutral); base revenue (ex-COVID) up 6.0% reported (+8.7% currency-neutral).
GAAP diluted EPS $1.53; adjusted diluted EPS $2.86, up 2.9% reported (+11.2% currency-neutral).
Company raises full-year base revenue and adjusted EPS guidance midpoints, enabling additional growth investments.
FDA approval for BD Onclarity HPV assay with SurePath and ThinPrep; BD Vaginal Panel cleared for BD COR system; BD Prevue II system launched.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BECTON DICKINSON & CO reported second quarter of fiscal 2023 results: revenue $4.8 billion, EPS $1.53. Guidance raised.

Period: second quarter of fiscal 2023
Revenue: $4.8 billion
EPS: $1.53
Guidance: raised
Result: reported results

Exact text from the filing

BD Reports Second Quarter Fiscal 2023 Financial Results BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges • Revenue of $4.8 billion increased 1.5% as reported and 4.1% on a currency-neutral basis • Revenue from base business (which excludes COVID-only diagnostic testing) grew 6.0% as reported, 8.7% currency-neutral • GAAP and adjusted diluted EPS from continuing operations of $1.53 and $2.86, respectively • Company raises full-year base revenue guidance, enabling additional investments in growth and innovation while absorbing lower COVID-only diagnostic testing revenue and incremental FX impacts

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BECTON DICKINSON & CO filing history →

Source: SEC EDGAR

accession 0000010795-23-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.